文献速递心力衰竭与心肌病

右内脏大神经血管内消融治疗射血分数保留的心力衰竭:REBALANCE-HF随机临床试验

Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

REBALANCE-HF是一项2期双盲假手术对照多中心随机试验,纳入90例HFpEF且运动峰值PCWP≥25 mmHg的患者。结果显示右内脏大神经血管内消融安全可行,但1个月时未降低运动PCWP,12个月临床结局亦无改善。

要点

  • SAVM在HFpEF患者中安全可行,不良事件与假手术组无差异。
  • 12个月心衰住院、运动功能及健康状况等次要终点均无差异。

核心结论

  • SAVM安全且技术可行,但未降低1个月运动PCWP或改善12个月临床结局。

研究设计与样本

  • 2期双盲1:1假手术对照多中心随机试验,在美国14个中心及格鲁吉亚共和国1个中心开展。
  • 纳入HFpEF、LVEF≥40%且侵入性测得运动峰值PCWP≥25 mmHg的患者90例(SAVM组44例,假手术组46例)。

主要发现

  • 次要疗效终点(心衰住院、运动功能、健康状况至12个月及静息/抬腿/20W运动PCWP变化)均无差异。

临床怎么用

  • 当前证据不支持将右内脏大神经血管内消融用于HFpEF患者的常规容量管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Greater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF). OBJECTIVE: To explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM). DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted at 14 centers in the US and 1 center in the Republic of Georgia. Patients with HFpEF, left ventricular ejection fraction of 40% or greater, and invasively measured peak exercise pulmonary capillary wedge pressure (PCWP) of 25 mm Hg or greater were included. Study data were analyzed from May 2023 to June 2024. INTERVENTION: SAVM vs sham control procedure. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a reduction in legs-up and exercise PCWP at 1 month. The primary safety end point was serious device- or procedure-related adverse events at 1 month. Secondary efficacy end points included HF hospitalizations, changes in exercise function and health status through 12 months, and baseline to 1-month change in resting, legs-up, and 20-W exercise PCWP. RESULTS: A total of 90 patients (median [range] age, 71 [47-90] years; 58 female [64.4%]) were randomized at 15 centers (44 SAVM vs 46 sham). There were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM or sham (mean between-group difference in PCWP, -0.03 mm Hg; 95% CI, -2.5 to 2.5 mm Hg; P = .95). There were also no differences in the secondary efficacy end points. There was no difference in the primary safety end point between the treatment (6.8% [3 of 44]) and sham (2.2% [1 of 46]) groups (difference, 4.6%; 95% CI, -6.1% to 15.4%; P = .36). There was no difference in the incidence of orthostatic hypotension between the treatment (11.4% [5 of 44]) and sham (6.5% [3 of 46]) groups (difference, 4.9%; 95% CI, -9.2% to 18.8%; P = .48). CONCLUSIONS AND RELEVANCE: Results show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04592445.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Fudim, Borlaug, Mohan, et al. Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 39356530. doi:10.1001/jamacardio.2024.2612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。